Mimi Evans, financial professional with the Bulfinch Group, the founder and CEO of Fast Turtle Ventures Mimi Evans-1.pdf
Chris Stepanian, President and CEO, Windgap Medical, Inc. Jack's Deck v2.pdf
Jack M. Swig, Attorney at Law and Counsel at Finance Chris Stepanian.pdf
So you and your co-founding team want to start a company? Starting a company without carefully considering some important co-founder questions and issues can significantly undermine your company’s chances of success. What questions should you consider when dividing the initial equity? What do you need to do to ensure the company’s ownership of IP? How do you protect your company and your investors if a co-founder stops working or leaves the company?
To answer these questions, our panel will discuss start-up formalization using founder agreements. These agreements define each team member’s roles and responsibilities as they will appear in legal filings. Equity ownership and vesting will be addressed as will the impact of unequal founder initial investment. Another essential aspect of technology start-ups is intellectual property (IP) ownership. Will some of the founders bring IP with them to the new venture? If so, IP ownership and licensing issues must be settled.
These are just a few of the issues our panel of experienced experts will address on November 3rd. You will also have the opportunity to ask your own questions and to network with others who, like yourself, will be start-up founders.
Mimi Evans is a financial professional with the Bulfinch Group, the founder and CEO of Fast Turtle Ventures, and the co-founder and CEO of SalesQuest, a marketing intelligence platform that was acquired by OneSource (now Avention) in 2014. Prior to becoming an entrepreneur Mimi served in sales leadership roles for several large technology companies, including IBM, Netscape, and Lotus. In addition to advising clients, entrepreneurs, start-ups, and small businesses Mimi serves as a Judge and Mentor for Mass Challenge 2015.
Chris Stepanian, President and CEO, Windgap Medical, Inc.
Chris Stepanian is a co-founder of Windgap Medical, Inc. ( www.windgapmedical.com ) and has served as President, CEO, and board-member since the Company’s founding. Windgap has developed and is commercializing its patent-pending wet/dry autoinjector platform and proprietary drug formulation to address major deficiencies in the epinephrine autoinjector market, a $1.3 billion dollar opportunity. He has also helped to raise $6.5 million in equity funding from angel, venture, and strategic sources. Windgap’s series A round of investment, just closed, is one of the largest angel/venture co-investment deals in the US this year. He is a long-time entrepreneur with more than 25 years of experience in operations, finance, strategy, and technology. He has experience in aerospace, automotive, contract-research, industrial materials, and healthcare industries. Previously he was a founding team member of Aspen Aerogels ( www.aerogel.com ) in Northborough, MA where he contributed to research, operations, and finance. He is a long-time organizer of the Head of the Charles Regatta® and a former board member of Community Rowing, Inc. He has engineering degrees from Rensselaer and Texas A&M along with an MBA from MIT’s Sloan Fellows program.
Jack M. Swig, Attorney at Law and Counsel at Finance
Mr. Swig’s background and experience span that of senior legal function, private merchant banking, corporate finance and venture capital in diverse roles including lending, bridge financing, and as a venture capital fund manager and in-house counsel in the medical diagnostics, devices and therapeutics sectors. He is well versed in the areas of business and strategic development and corporate alliance. He has, during several periods in his career, been deeply involved in crisis management and developed acumen in turnarounds, workouts and asset recovery with varying stages of private and public enterprises. Prior to undertaking his specialty law and finance practice, he served for more than 12 years as Vice President of Corporate Development and General Counsel for Microfluidics International Corporation (formerly public – MFLU; acquired in 2012 by IDEX Corporation (NYSE: IEX), and its subsidiary, Microfluidics Corporation). Mr. Swig also served as the company’s Investor Relations Manager for almost 15 years, often working with market makers and analysts. Since 2011, Mr. Swig has served, part-time, as In-house Counsel, strategic planner, a capital and funding resource development and coordinator for a Biotech/Medical Device and Cleantech non-profit incubator (that he helped to create and develop). He Interacts with and advises the CEO, COO and Chairman with regard to a wide range of day to day, special project and strategic planning activities. His responsibilities include all legal agreements, technical and business evaluation, due diligence investigation of applicants, needs assessment for applicant companies, assisting portfolio companies with identifying financing prospects and presentations and collaborations.
Since mid-2008 Mr. Swig has been a sole practitioner in his legal and finance consulting practice working extensively with early stage companies on corporate development, financing, strategic partnerships and alliances, and a wide range of matters with clients from pharmaceutical R&D, Life Science Research Tools, Medical Devices, Healthcare, and Cleantech/Energy Savings sectors. His legal work generally revolves around corporate and securities matters, confidentiality, material transfer and related agreements, Intellectual Property strategy and licensing.
Greg Dawe, https://www.linkedin.com/in/gregdawe
Greg Dawe is ENET's Vice Chair of Operations and has been working in the software industry for over 30 years, first as an engineer, and later, in management. For over 10 years, he held senior management positions in the computer network security industry including experience with RSA Security, Inc.
Greg specializes in establishing and growing new organizations directly linked to improving company results.